Puriblood Medical Co (6847) Fair Value & Analysis
Healthcare · TW · Market cap 1.0B TWD
Fair value as of: Jul 23, 2026
From 1 valuation models · updated 18 days ago
Fair value updated Jul 23, 2026, revised from 60.99 TWD to 61.52 TWD (+0.9%) since Jul 12, 2026. Share price −2.5% over the past month.
Below-average quality, and screening another 22% overvalued on our models.
What matters now
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (40.80 TWD to 77.06 TWD) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 23, 2026.
How to read this chart
8‑month range 47.85 TWD – 88.70 TWD · fair‑value band 40.80 TWD – 77.06 TWD · the 78.50 TWD price screens above the 61.52 TWD fair value. As of Jul 23, 2026.
Analysis
Puriblood Medical Co (6847) currently trades at 78.50 TWD, while our model-based Fair Value estimate is 61.52 TWD, implying the stock looks roughly 21.6% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Puriblood Medical Co generated revenue of 82.3M TWD at a net margin of -47.4%. Revenue declined 45.4% year over year. It earns a return on equity of -24.7%. The balance sheet holds a net cash position of 34.8M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 40.80 TWD (bear case) to 77.06 TWD (bull case); at 78.50 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 16% below its 52-week high and 64% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -22%, 6847 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 6847 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 47 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd.
Full company description
Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Puriblood Medical Co reported revenue of 82.3M TWD in FY2025 versus 54.6M TWD in FY2021, a compound +10.8%/yr. Reported net income was −39.0M TWD in FY2025.
6847 screens 22% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Puriblood Medical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Puriblood Medical Co (6847) overvalued or undervalued?
What is the fair value of 6847?
What is the quality score of 6847?
What is the revenue of Puriblood Medical Co (6847)?
What is the net profit margin of 6847?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Puriblood Medical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.